Insights from 5 Years of RISE and RIDE

In this interview from ASRS 2016, Dr. Rishi Singh discusses insights from 5 years of data from the RISE and RIDE studies evaluating ranibizumab in patients with DME. Data showed that changes in macular anatomy do not always correspond to changes in visual acuity, and that macular perfusion – once thought an indicator of poor visual prognosis - is reversible. In addition, patients with diabetic retinopathy were found to have an average 2-3 step improvement, with the strongest gains seen in those with severe NPDR. Based on these studies, Dr. Singh reassures his retinopathy patients that positive long-term vision and retinal health outcomes are possible with anti-VEGF therapy.